Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar;212(4):152-153.e1.
doi: 10.5694/mja2.50474. Epub 2020 Feb 9.

Tafenoquine for the radical cure and prevention of malaria: the importance of testing for G6PD deficiency

Robert J Commons  1   2   3 , James S McCarthy  4   5 , Ric N Price  1   6   7
Affiliations

Tafenoquine for the radical cure and prevention of malaria: the importance of testing for G6PD deficiency

Robert J Commons et al. Med J Aust. 2020 Mar.
No abstract available

Keywords: Anti-infective agents; Malaria.

PubMed Disclaimer

Conflict of interest statement

Ric Price is a Wellcome Trust Senior Fellow in Clinical Science (200909).

Ric Price was on the expert panel for the tafenoquine licensing application at the US Federal Drug Administration and on the expert committee for the Australian Therapeutic Goods Administration. His travel expenses to the US were reimbursed by GlaxoSmithKline. James McCarthy received funding from 60 Degrees Pharmaceuticals to conduct a randomised controlled trial to test the activity of tafenoquine as a potential drug for the chemoprophylaxis of malaria.

References

    1. Baird JK. Primaquine toxicity forestalls effective therapeutic management of the endemic malarias. Int J Parasitol 2012; 42: 1049–1054. - PubMed
    1. Baird JK. Tafenoquine for travelers’ malaria: evidence, rationale and recommendations. J Travel Med 2018; 25: tay100. - PMC - PubMed
    1. Brueckner RP, Lasseter KC, Lin ET, Schuster BG. First‐time‐in‐humans safety and pharmacokinetics of WR 238605, a new antimalarial. Am J Trop Med Hyg 1998; 58: 645–649. - PubMed
    1. Llanos‐Cuentas A, Lacerda MV, Rueangweerayut R, et al. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double‐blind, randomised, phase 2b dose‐selection study. Lancet 2014; 383: 1049–1058. - PubMed
    1. Chu CS, Freedman DO. Tafenoquine and G6PD: A Primer for Clinicians. J Travel Med 2019; 26: taz023. - PMC - PubMed